作者
Mio Nakamura, Katherine Lee, Caleb Jeon, Sahil Sekhon, Ladan Afifi, Di Yan, Kristina Lee, Tina Bhutani
发表日期
2017/9
来源
Dermatology and therapy
卷号
7
页码范围
281-292
出版商
Springer Healthcare
简介
Introduction
Interleukin (IL)-23 inhibitors are a new class of biologics currently undergoing clinical trials for the treatment of moderate-to-severe psoriasis. Phase III studies of guselkumab, an IL-23 receptor monoclonal antibody, are currently underway.
Methods
We summarize the available phase III results to date, establishing the efficacy and safety of guselkumab in patients with moderate-to-severe plaque psoriasis.
Results
Currently, there are available data of up to 48 weeks from two Phase III, multicenter, randomized, double-blind, placebo- and comparator-controlled clinical trials, VOYAGE 1 and VOYAGE 2. At week 16, the proportion of patients attaining at least a 90% improvement from baseline in the Psoriasis Area and Severity Index (PASI 90) was 73.3% in VOYAGE 1 and 70.0% in VOYAGE 2. Guselkumab …
学术搜索中的文章
M Nakamura, K Lee, C Jeon, S Sekhon, L Afifi, D Yan… - Dermatology and therapy, 2017